Becton, Dickinson and Company

Equities

BDX

US0758871091

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 01:30:02 30/04/2024 am IST			5-day change	1st Jan Change
233.4 ^USD	+0.82%		-0.19%	-4.26%

26/04	Becton, Dickinson and Company acquired FlowJo LLC.	CI
05/04	Becton Dickinson Releases New Image-Enabled Cell Sorters	MT

Becton, Dickinson and Company announces an Equity Buyback for 10,000,000 shares.

November 04, 2021 at 03:35 pm IST

Becton, Dickinson and Company (NYSE:BDX) announces a share repurchase program. Under the program, the company will repurchase up to 10,000,000 shares of common stock. The program has no expiration date.

Latest news about Becton, Dickinson and Company

Becton, Dickinson and Company acquired FlowJo LLC.	26/04	CI
Becton Dickinson Releases New Image-Enabled Cell Sorters	05/04	MT
Becton, Dickinson and Company Increases Access to Cutting-Edge Image-Enabled, Spectral Cell Sorters	05/04	CI
AngioDynamics Settles Patent Dispute with Becton, Dickinson Affiliate	02/04	MT
AngioDynamics Settles Multi-Year Patent Dispute with Becton Dickinson & Co	02/04	DJ
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	22/03	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	22/03	MT
Sector Update: Health Care	22/03	MT
Becton, Dickinson Raising Domestic Production of Syringes	21/03	MT
Transcript : Becton, Dickinson and Company Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:30 AM	13/03
Becton, Dickinson and Co. Enrolls First Person in Trial of Stent to Treat Peripheral Arterial Disease	04/03	MT
Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease	04/03	CI
Transcript : Becton, Dickinson and Company Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 08:00 AM	29/02
Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024	27/02	CI
Becton, Dickinson Seeks M&A	27/02	CI
Transcript : Becton, Dickinson and Company - Special Call	27/02
Becton, Dickinson Collaborating With Camtech Health for at-Home Cervical Cancer Screening in Singapore	21/02	MT
Barclays Adjusts Price Target on Becton Dickinson and Co. to $305 From $301, Maintains Overweight Rating	05/02	MT
Tranche Update on Becton, Dickinson and Company's Equity Buyback Plan announced on November 4, 2021.	02/02	CI
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	01/02	MT
Transcript : Becton, Dickinson and Company, Q1 2024 Earnings Call, Feb 01, 2024	01/02
Becton, Dickinson's Fiscal Q1 Adjusted Earnings Down, Revenue Up; 2024 Guidance Revised	01/02	MT
Becton Dickinson Lifts 2024 Outlook After Sales Rise in 1Q	01/02	DJ
(BDX) BD (BECTON DICKINSON AND COMPANY) Sees Fiscal Year 2024 EPS Range $12.82 - $13.06	01/02	MT
Earnings Flash (BDX) BD (BECTON DICKINSON AND COMPANY) Posts Q1 Revenue $4.71B, vs. Street Est of $4.73B	01/02	MT

Chart Becton, Dickinson and Company

Duration

Period

More charts

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

02/05/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Becton, Dickinson and Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

233.4 USD

Average target price

279 USD

Spread / Average Target

+19.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BECTON, DICKINSON AND COMPANY	-4.26%	67.44B
ABBOTT LABORATORIES	-2.54%	186B
MEDTRONIC PLC	-1.85%	107B
DEXCOM, INC.	+1.39%	50.03B
CENCORA, INC.	+16.82%	47.81B
HOYA CORPORATION	+5.53%	41.03B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.49%	26.85B
WEST PHARMACEUTICAL SERVICES, INC.	+0.65%	25.82B
TERUMO CORPORATION	+17.29%	24.74B
ZIMMER BIOMET HOLDINGS, INC.	+0.01%	25.01B

Other Medical Equipment, Supplies & Distribution